Previous 10 | Next 10 |
Deciphera Pharmaceuticals is the unusual case of a commercial-stage company whose drug succeeds at first but then has a major setback. Top-line data from a key phase 3 trial suggest that their flagship drug will not be moving from later-line to second-line therapy for GIST. With b...
Shares of Deciphera Pharmaceuticals are (NASDAQ:DCPH) up 6% after the European Commission approved Qinlock (ripretinib) as a fourth-line treatment for gastrointestinal stromal tumors. A pivotal trial showed that the drug increased overall survival compared to best supportive care. It also mai...
Astra Space (NASDAQ:ASTR) +35% after successful commercial orbital launch iSpecimen (NASDAQ:ISPC) +26% selected by U.S. Government and private researchers to supply critical human biospecimens for advanced phase of COVID-19 research PainReform (NASDAQ:PRFX) +19%. Vonage Holding...
– QINLOCK Significantly Reduced the Risk of Disease Progression or Death by 85% and Showed Clinically Meaningful Overall Survival in the INVICTUS Phase 3 Study – Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a commercial-stage biopharmaceutical company de...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Short selling biotechnology stocks is a dangerous game to play. However, Deciphera Pharmaceuticals (NASDAQ: DCPH ) has been a boon to the bears as DCPH stock is far below its peak price. Source: Iryna Imago / Shut...
After a setback in a late-stage cancer trial wiped off more than three-quarters of its market cap on Friday, Deciphera Pharmaceuticals (NASDAQ:DCPH) has added ~3.4% in the pre-market. The Phase 3 INTRIGUE designed to assess Qinlock as a potential treatment for a certain group of pat...
Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks rallied to fresh record highs Friday following a stronger than expected jobs report that showed 531,000 jobs added in October and a re...
Friday's standout performers were largely defined by their relationship to Pfizer. The drug maker announced blockbuster results from a clinical trial of its COVID pill, revealing an 89% reduction in risk for hospitalization or death. In response, travel stocks rallied, including substantial g...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Any time a stock moves down 75% over a given period of time, investors have reason to be concerned. When such a move happens in a given trading day, it’s time to ring the alarm bells. For investors in Deciphera Ph...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “Deciphera Pharmaceuticals, Inc. Shares Fell 73% After its INTRIGUE Phase 3 Clinical Study Failed to Meet its Primary Endpoint” Deciphera Pharmaceuticals, I...
News, Short Squeeze, Breakout and More Instantly...
Deciphera Pharmaceuticals Inc. Company Name:
DCPH Stock Symbol:
NASDAQ Market:
Deciphera Pharmaceuticals Inc. Website:
– MOTION Phase 3 Data Demonstrate Robust Efficacy, Clinically Meaningful Improvements in Quality-of-Life Measures, and Well-Tolerated Safety Profile, Positioning Vimseltinib as Potential New TGCT Treatment – – Company Expects to Submit a New Drug Application (NDA) in ...
Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...